> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# RapidAI RV/LV Analyzer for Pulmonary Embolism Cleared
- URL: https://www.fdaweb.com/rapidai-rv-lv-analyzer-for-pulmonary-embolism-cleared/
- Published: 2023-02-22T12:00:00.000Z
- Updated: 2026-09-14T18:16:47.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5153834

FDA has cleared a RapidAI 510(k) for Rapid RV/LV, a tool for physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity. “Automating this process will enable care teams to more quickly prioritize patients and accelerate decision making,” the company says.

The device uses artificial intelligence to analyze computerized tomography pulmonary angiograms and automatically calculate the RV/LV ratio within minutes of the scan. It is combined with the company’s Rapid PE triage and notification product to provide PE care teams with information to make faster care decisions, the company says, adding that the key benefits include identifying those with possible right heart strain and reduced RV/LV measurement variability.